|
1
|
Pinana JL, Martino R, Garcia-Garcia I,
Parody R, Morales MD, Benzo G, Gómez-Catalan I, Coll R, De La
Fuente I, Luna A, et al: Risk factors and outcome of COVID-19
inpatients with hematological malignancies. Exp Hematol Oncol.
9(21)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vijenthira A, Gong IY, Fox TA, Booth S,
Cook G, Fattizzo B, Martin-Moro F, Razanamahery J, Riches JC,
Zwicker J, et al: Outcomes of patients with hematologic
malignancies and COVID-19: A systematic review and meta-analysis of
3377 patients. Blood. 136:2881–2892. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Asch DA, Sheils NE, Islam MN, Chen Y,
Werner RM, Buresh J and Doshi JA: Variation in US hospital
mortality rates for patients admitted with COVID-19 during the
first 6 months of the pandemic. JAMA Intern Med. 181:471–478.
2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sun C, Pleyer C and Wiestner A: COVID-19
vaccines for patients with hematological conditions. Lancet
Haematol. 8:e312–e314. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Riester E, Findeisen P, Hegel JK, Kabesch
M, Ambrosch A, Rank CM, Pessl F, Laengin T and Niederhauser C:
Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S
immunoassay. J Virol Methods. 297(114271)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Feng S, Phillips DJ, White T, Sayal H,
Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, et al:
Correlates of protection against symptomatic and asymptomatic
SARS-CoV-2 infection. Nat Med. 27:2032–2040. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Perkmann T, Perkmann-Nagele N, Koller T,
Mucher P, Radakovics A, Marculescu R, Wolzt M, Wagner OF, Binder CJ
and Haslacher H: Anti-Spike protein assays to determine SARS-CoV-2
antibody levels: A head-to-head comparison of five quantitative
assays. Microbiol Spectr. 9(e0024721)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Perry C, Luttwak E, Balaban R, Shefer G,
Morales MM, Aharon A, Tabib Y, Cohen C, Benyamini N, Beyar-Katz O,
et al: Efficacy of the BNT162b2 mRNA COVID-19 vaccine patients with
B-cell non-Hodgkin lymphoma. Blood Adv. 5:3053–3061.
2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Re D, Barriere J, Chamorey E, Delforge M,
Gastaud L, Petit E, Chaminade A, Verrriere B and Peyrade F: Low
rate of seroconversion after m RNA anti-SARS-CoV-2 vaccination in
patients with hematological malignancies. Leuk Lymphoma.
62:3308–3310. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Avivi I, Luttwak E, Saiang E, Halperin T,
Haberman S, Saring A, Levi S, Aharon A, Herishanu Y and Perry C:
BNT-162b2 m RNA COVID-19 vaccine booster induces seroconversion in
patients with B-cell non-Hodgkin lymphoma who failed to respond to
two prior vaccine doses. Br J Haematol. 196:1329–1333.
2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Moor MB, Suter-Riniker F, Horn MP, Aeberli
D, Amsler J, Möller B, Njue LM, Medri C, Angelillo-Scherrer A,
Borradori L, et al: Humoral and cellular responses to mRNA vaccines
against SARS-CoV-2 in patients with a history of CD20
B-cell-depleting therapy (RituxiVac): An investigator-initiated,
single-centre, open-label study. Lancet Rheumatol. 3:e789–e797.
2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Schubert L, Koblischke M, Schneider L,
Porpaczy E, Winkler F, Jaeger U, Blüml S, Haslacher H, Burgmann H,
Aberle JH, et al: Immunogenicity of COVID-19 vaccinations in
hematological patients: 6-month follow-up and evaluation of a 3rd
vaccination. Cancers (Basel). 14(1962)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tsushima T, Terao T, Narita K, Fukumoto A,
Ikeda D, Kamura Y, Kuzume A, Tabata R, Miura D, Takeuchi M and
Matsue K: Antibody response to COVID-19 vaccine in 130 recipients
of hematopoietic stem cell transplantation. Int J Hematol.
115:611–615. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Narita K, Nakaji S, Tabata R, Terao T,
Kuzume A, Tsushima T, Ikeda D, Fukumoto A, Miura D, Takeuchi M, et
al: Antibody response to COVID-19 vaccination in patients with
lymphoma. Int J Hematol. 115:728–736. 2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Antolí A, Rocamora-Blanch G, Framil M,
Mas-Bosch V, Navarro S, Bermudez C, Martinez-Yelamos S, Dopico E,
Calatayud L, Garcia-Muñoz N, et al: Evaluation of Humoral and
Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients
With Common Variable Immunodeficiency Phenotype and Patient
Receiving B-Cell Depletion Therapy. Front Immunol.
13(895209)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ram R, Hagin D, Kikozashvilli N, Freund T,
Amit O, Bar-On Y, Beyar-Katz O, Shefer G, Moshiashvili MM, Karni C,
et al: Safety and Immunogenicity of the BNT162b2 mRNA COVID-19
vaccine in patients after allogeneic HCT or CD19-based CART
therapy-A single-center prospective cohort study. Transplant Cell
Ther. 27:788–794. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jarisch A, Wiercinska E, Huenecke S, Bremm
M, Cappel C, Hauler J, Rettinger E, Soerensen J, Hellstern H,
Klusmann JH, et al: Immune Responses to SARS-CoV-2 vaccination in
young patients with Anti-CD19 chimeric antigen receptor T
cell-induced B Cell Aplasia. Transplant Cell Ther.
28:366.e1–366.e7. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Baron F, Canti L, Ariën KK, Kemlin D,
Desombere I, Gerbaux M, Pannus P, Beguin Y, Marchant A and
Humblet-Baron S: . Insights from early clinical trials assessing
response to mRNA SARS-CoV-2 vaccination in immunocompromised
patients. Front Immunol. 13(827242)2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Duni A, Markopoulos GS, Mallioras I,
Pappas H, Pappas E, Koutlas V, Tzalavra E, Baxevanos G, Priska S,
Gartzonika K, et al: The humoral immune response to BNT162b2
vaccine is associated with circulating CD19+ B lymphocytes and the
naïve CD45RA to Memory CD45RO CD4+ T helper cells ratio in
hemodialysis patients and kidney transplant recipients. Front
Immunol. 12(760249)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ishio T, Tsukamoto S, Yokoyama E,
Izumiyama K, Saito M, Muraki H, Kobayashi M, Mori A, Morioka M and
Kondo T: Anti-CD20 antibodies and bendamustine attenuate humoral
immunity to COVID-19 vaccination in patients with B-cell
non-Hodgkin lymphoma. Ann Hematol. 102:1421–1431. 2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Liebers N, Speer C, Benning L, Bruch PM,
Kraemer I, Meissner J, Schnitzler P, Kräusslich HG, Dreger P,
Mueller-Tidow C, et al: Humoral and cellular responses after
COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood.
139:142–147. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nishikubo M, Shimomura Y, Yamamoto R,
Yoshioka S, Maruoka H, Nasu S, Nishioka T, Sakizono K, Mitsuyuki S,
Kubo T, et al: Humoral and cellular responses after COVID-19
booster vaccination in patients recently treated with anti-CD20
antibodies. Blood Cancer J. 13(17)2023.PubMed/NCBI View Article : Google Scholar
|
